yutrepia

Generic: treprostinil

yutrepia: developed by 1 company · 2 FDA decisions. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
Liquidia Corp (LQDA)Approved

FDA Decisions

PDUFA1 INDICATIONS AND USAGE • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately i(LQDA)
Approval1 INDICATIONS AND USAGE • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately i(LQDA)

Frequently asked questions

Who is developing yutrepia?

yutrepia is being developed by Liquidia Corp.

What is yutrepia's latest FDA decision?

The most recent tracked FDA decision for yutrepia is PDUFA for 1 INDICATIONS AND USAGE • Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately i, dated May 24, 2025.

Get deeper analysis on yutrepia

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    yutrepia — Drug Pipeline, Trials & FDA Status | BioSniper